<p>高盛分析師 Corinne Johnson 今天對 Immunovant 維持了持有評級，並設定了 28.00 美元的目標價。</p>
<h3>在 TipRanks Premium 上享受 50% 的折扣，放心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>Johnson 覆蓋醫療保健行業，關注的股票包括 Roivant Sciences、Rhythm Pharmaceuticals 和 Halozyme。根據 TipRanks 的數據，Johnson 推薦股票的平均回報率為 7.5%，成功率為 54.07%。</p>
<p>除了高盛，Immunovant 還在今天的報告中獲得了 Truist Financial 的 Danielle Brill 的持有評級。然而，在同一天，LifeSci Capital 對 Immunovant（NASDAQ: IMVT）維持了買入評級。</p>

IMVT

<p>高盛分析師 Corinne Johnson 對 Immunovant 維持了持有評級，目標價為 28.00 美元。Johnson 負責醫療保健行業，平均回報率為 7.5%，成功率為 54.07%。Truist Financial 也發佈了持有評級，而 LifeSci Capital 則對 Immunovant 維持了買入評級</p>

<p>Goldman Sachs analyst Corinne Johnson maintained a Hold rating on Immunovant today and set a price target of $28.00.</p>
<div class="lb-trans"><p>高盛分析師 Corinne Johnson 今天對 Immunovant 維持了持有評級，並設定了 28.00 美元的目標價。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 的折扣，放心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>Johnson covers the Healthcare sector, focusing on stocks such as Roivant Sciences, Rhythm Pharmaceuticals, and Halozyme. According to TipRanks, Johnson has an average return of 7.5% and a 54.07% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Johnson 覆蓋醫療保健行業，關注的股票包括 Roivant Sciences、Rhythm Pharmaceuticals 和 Halozyme。根據 TipRanks 的數據，Johnson 推薦股票的平均回報率為 7.5%，成功率為 54.07%。</p>
</div><p>In addition to Goldman Sachs, Immunovant also received a Hold from Truist Financial’s Danielle Brill in a report issued today. However, on the same day, LifeSci Capital maintained a Buy rating on Immunovant (NASDAQ: IMVT).</p>
<div class="lb-trans"><p>除了高盛，Immunovant 還在今天的報告中獲得了 Truist Financial 的 Danielle Brill 的持有評級。然而，在同一天，LifeSci Capital 對 Immunovant（NASDAQ: IMVT）維持了買入評級。</p>
</div>

高盛對 Immunovant (IMVT) 維持持有評級